Table 5.
Strain | Trial | Mean lifespan ± SEM | Events/obs | Percentage difference compared with N2 | p value summary vs N2 | p value summary vs pgrn-1(-) |
---|---|---|---|---|---|---|
N2 | 1 | 15.1 ± 0.7 | 68/90 | — | — | — |
pgrn-1(tm985) | 15.0 ± 0.6 | 77/90 | −0.7 | ns | — | |
pgrn-1(-);TDP-43 | 12.6 ± 0.7 | 68/90 | −16.6 | ns | ns | |
pgrn-1(-);gran3 | 15.9 ± 0.9 | 57/90 | 5.3 | ns | ns | |
pgrn-1(-);TDP-43;gran3 | 8.1 ± 0.4 | 71/90 | −46.4 | *** | *** | |
N2 | 2 | 16.4 ± 0.8 | 72/90 | — | — | — |
pgrn-1(-) | 15.0 ± 0.8 | 60/90 | −8.5 | ns | — | |
pgrn-1(-);TDP-43 | 13.3 ± 0.7 | 73/90 | −18.9 | ** | ns | |
pgrn-1(-);gran3 | 17.4 ± 1.0 | 39/90 | 6.1 | ns | ns | |
pgrn-1(-);TDP-43;gran3 | 8.9 ± 0.5 | 74/90 | −45.7 | *** | *** |
Two independent lifespan trials were performed on strains as indicated. Average lifespans of strains were compared using the Mantel–Cox statistical test (ns, not significant;
**p < 0.01,
***p < 0.0001).